Pharmaceutical

Investors anticipate “bounce-back” in European private investment

Investors anticipate “bounce-back” in European private ...

Apr 25, 2024

At the Swiss Biotech Day conference, panelists at an investment talk discussed t...

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic...

Apr 23, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and curre...

Datopotamab deruxtecan by Daiichi Sankyo for Non Muscle...

Apr 23, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and curre...

Datopotamab deruxtecan by Daiichi Sankyo for Head And N...

Apr 23, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and curre...

Datopotamab deruxtecan by Daiichi Sankyo for Epithelial...

Apr 23, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and curre...

Datopotamab deruxtecan by Daiichi Sankyo for Peritoneal...

Apr 23, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and curre...

Datopotamab deruxtecan by Daiichi Sankyo for Transition...

Apr 23, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and curre...

Farletuzumab ecteribulin by Eisai for Ovarian Cancer: L...

Apr 23, 2024

Farletuzumab ecteribulin is under clinical development by Eisai and currently in...

AlphaMedix by Orano Med for Neuroendocrine Gastroentero...

Apr 23, 2024

AlphaMedix is under clinical development by Orano Med and currently in Phase II ...

Lorcaserin hydrochloride by EpyGenix Therapeutics for D...

Apr 23, 2024

Lorcaserin hydrochloride is under clinical development by EpyGenix Therapeutics ...

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic...

Apr 23, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and curre...

DF-4101 by AbbVie for Renal Cell Carcinoma: Likelihood ...

Apr 21, 2024

DF-4101 is under clinical development by AbbVie and currently in Phase I for Ren...

DF-4101 by AbbVie for Head And Neck Squamous Cell Carci...

Apr 21, 2024

DF-4101 is under clinical development by AbbVie and currently in Phase I for Hea...

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likel...

Apr 21, 2024

DF-4101 is under clinical development by AbbVie and currently in Phase I for Non...

PRO-1107 by ProfoundBio Suzhou for Gastric Cancer: Like...

Apr 21, 2024

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Ph...

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelih...

Apr 21, 2024

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Ph...